CL
CRSP icon

Choreo LLC’s CRISPR Therapeutics CRSP Stock Holding History

Choreo LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$338K Sell
7,114
-975
-12% -$51.4K ﹤0.01% 1176
2025
Q4 		$430K Buy
8,089
+443
+6% +$26.5K 0.01% 996
2025
Q3 		$496K Buy
7,646
+1,631
+27% +$93.6K 0.01% 930
2025
Q2 		$293K Buy
+6,015
New +$233K ﹤0.01% 1193
2024
Q3 		– Sell
-4,047
Closed -$218K – 1640
2024
Q2 		$218K Buy
+4,047
New +$234K ﹤0.01% 1287

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Choreo LLC's CRSP Position: Q1 2026 in Review

Choreo LLC reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $51.4K and leaving 7,114 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Choreo LLC first reported a position in CRSP in Q2 2024 and has held it in 5 quarters since. The position peaked at $496K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Choreo LLC held 7,114 shares of CRISPR Therapeutics worth $338K as of Q1 2026.
  • Choreo LLC sold 975 CRISPR Therapeutics shares in Q1 2026, an estimated $51.4K.
  • CRISPR Therapeutics made up ﹤0.01% of Choreo LLC's portfolio in Q1 2026, its #1176 holding.
  • Choreo LLC first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Choreo LLC's CRISPR Therapeutics position peaked at $496K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.